Merck KGaA to acquire SpringWorks Therapeutics for $3.9 billion, strengthening position in biopharmaceutical industry

From Nasdaq: 2025-04-28 02:34:00

Merck KGaA has agreed to acquire SpringWorks Therapeutics for $3.9 billion, with a purchase price of $47 per share in cash. The deal is expected to be immediately accretive to earnings per share pre in 2027. SpringWorks is known for its standard-of-care therapy for desmoid tumors and the first approved therapy for neurofibromatosis type 1-associated plexiform neurofibromas. This acquisition will strengthen Merck KGaA’s position in the biopharmaceutical industry. For more health news, visit rttnews.com. (Source: RTTNews)



Read more at Nasdaq: Merck KGaA To Acquire SpringWorks